After the phase 2/3 study for a COVID-19 vaccine was suspended, AstraZeneca has restarted the study in the UK. According to news, the UK drug health regulator, which conducted clinical trials overseas, recommended continuing. The trial was temporarily stopped on September 6th when a volunteer who had received the vaccine fell ill.
The break should allow researchers to find out if the disease was related to the vaccine or a coincidence. It is not yet known whether the US, Brazil and South Africa trials will resume.
The company has not released any additional information at the time of this writing. However, previous reports suggested that the volunteer had developed transverse myelitis, an inflammation of the spinal cord.
"AstraZeneca and the University of Oxford as sponsors of the study cannot disclose any further medical information," the company said in a statement. "All investigators and participants in the study will be updated with the relevant information and this will be published in global clinical registries in accordance with clinical trial standards and regulatory requirements."